Melanocyte-specific gene 1 promotes melanoma progression by enhancing the expression of Bcl-2

Zhao,Hui; Wu,Guosheng; Zhu,Ji; Sun,Mengyan; Wang,Yuchong; Fan,Yongjie; Wu,Kai; Bi,Hongda; Dai,Haiying; Lv,Chuan; Xue,Chunyu

doi:10.3892/ol.2017.7592

Melanocyte-specific gene 1 promotes melanoma progression by enhancing the expression of Bcl-2

Authors:
- Hui Zhao
- Guosheng Wu
- Ji Zhu
- Mengyan Sun
- Yuchong Wang
- Yongjie Fan
- Kai Wu
- Hongda Bi
- Haiying Dai
- Chuan Lv
- Chunyu Xue
View Affiliations

Affiliations: Department of Plastic Surgery, Changhai Hospital, Shanghai 200433, P.R. China, Department of Burn Surgery, Changhai Hospital, Shanghai 200433, P.R. China
Published online on: December 12, 2017 https://doi.org/10.3892/ol.2017.7592
Pages: 2413-2418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma is a class of highly malignant tumors derived from melanocytes. At present, the dysregulated gene expression involved in the progression of melanoma has attracted much attention. In the present study, the gene expression profile of human melanoma tissue was screened using a cDNA microarray, and it was identified that melanocyte‑specific gene 1 (MSG1) was significantly overexpressed in melanoma tissue compared with paired nevus tissues. The overexpression of MSG1 in melanoma was subsequently confirmed using immunohistochemistry in a set of melanoma tissues. It was additionally identified that the overexpression of MSG1 may promote cell viability and inhibit cell apoptosis in human melanoma A375 cells, thus promoting melanoma progression. Mechanistically, following screening of the expression of apoptosis‑associated proteins, MSG1 was demonstrated to enhance the expression of the apoptosis inhibitor B‑cell lymphoma 2 (Bcl‑2) to inhibit melanoma cell apoptosis. Therefore, it was concluded that the overexpression of MSG1 inhibits apoptosis by enhancing Bcl‑2 expression in malignant melanoma, thus promoting melanoma progression.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
3	Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
4	Ortega E, Marti RM, Yeramian A, Sorolla A, Dolcet X, Llobet D, Abal L, Santacana M, Pallares J, Llombart-Cussac A and Matias-Guiu X: Targeted therapies in gynecologic cancers and melanoma. Semin Diagn Pathol. 25:262–273. 2008. View Article : Google Scholar : PubMed/NCBI
5	Terheyden P, Tilgen W and Hauschild A: Recent aspects of medical care of malignant melanoma. J Dtsch Dermatol Ges. 6:868–878. 2008.(In English, German). View Article : Google Scholar : PubMed/NCBI
6	di Pietro A, Tosti G, Ferrucci PF and Testori A: Oncophage: Step to the future for vaccine therapy in melanoma. Expert Opin Biol Ther. 8:1973–1984. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, et al: Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell. 25:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
8	Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sumantran VN, Mishra P and Sudhakar N: Microarray analysis of differentially expressed genes regulating lipid metabolism during melanoma progression. Indian J Biochem Biophys. 52:125–131. 2015.PubMed/NCBI
10	Dadras SS, Lin RJ, Razavi G, Kawakami A, Du J, Feige E, Milner DA, Loda MF, Granter SR, Detmar M, et al: A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression. Am J Pathol. 185:252–265. 2015. View Article : Google Scholar : PubMed/NCBI
11	Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, et al: Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication. Cancer Genet. 207:306–315. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, Elashoff D, Kiyohara E, Irie RF, Morton DL and Hoon DS: Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem. 60:873–885. 2014. View Article : Google Scholar : PubMed/NCBI
13	Han B, Liu N, Yang X, Sun HB and Yang YC: MRG1 expression in fibroblasts is regulated by Sp1/Sp3 and an Ets transcription factor. J Biol Chem. 276:7937–7942. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ and Shioda T: The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem. 275:8825–8834. 2000. View Article : Google Scholar : PubMed/NCBI
15	Nair SS, Chaubal VA, Shioda T, Coser KR and Mojamdar M: Over-expression of MSG1 transcriptional co-activator increases melanin in B16 melanoma cells: A possible role for MSG1 in melanogenesis. Pigment Cell Res. 14:206–209. 2001. View Article : Google Scholar : PubMed/NCBI
16	Ahmed NU, Shioda T, Coser KR, Ichihashi M and Ueda M: Aberrant expression of MSG1 transcriptional activator in human malignant melanoma in vivo. Pigment Cell Res. 14:140–143. 2001.PubMed/NCBI
17	Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z and Cao X: MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol. 183:2150–2158. 2009. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Martinez-Cardús A, Vizoso M, Moran S and Manzano JL: Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance. Ann Transl Med. 3:2092015.PubMed/NCBI
20	Elder DE: Pathology of melanoma. Surg Oncol Clin N Am. 24:229–237. 2015. View Article : Google Scholar : PubMed/NCBI
21	Bartlett EK and Karakousis GC: Current staging and prognostic factors in melanoma. Surg Oncol Clin N Am. 24:215–227. 2015. View Article : Google Scholar : PubMed/NCBI
22	Higgins HW II, Lee KC, Galan A and Leffell DJ: Melanoma in situ: Part II. Histopathology, treatment, and clinical management. J Am Acad Dermatol. 73:193–203. 2015. View Article : Google Scholar : PubMed/NCBI
23	Stenzel M, Tura A, Nassar K, Rohrbach JM, Grisanti S, Lüke M and Lüke J: Analysis of caveolin-1 and phosphoinositol-3 kinase expression in primary uveal melanomas. Clin Experiment Ophthalmol. 44:400–409. 2016. View Article : Google Scholar : PubMed/NCBI
24	Talaiezadeh A, Jalali F, Galehdari H and Khodadadi A: Time depended Bcl-2 inhibition might be useful for a targeted drug therapy. Cancer Cell Int. 15:1052015. View Article : Google Scholar : PubMed/NCBI
25	Mukherjee N, Schwan JV, Fujita M, Norris DA and Shellman YG: Alternative treatments for melanoma: Targeting BCL-2 family members to De-Bulk and kill cancer stem cells. J Invest Dermatol. 135:2155–2161. 2015. View Article : Google Scholar : PubMed/NCBI
26	Hartman ML and Czyz M: Pro-survival role of MITF in melanoma. J Invest Dermatol. 135:352–358. 2015. View Article : Google Scholar : PubMed/NCBI
27	Brazel AJ and Vernimmen D: The complexity of epigenetic diseases. J Pathol. 238:333–344. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ambrosone CB, Hong CC and Goodwin PJ: Host factors and risk of breast cancer recurrence: Genetic, epigenetic and biologic factors and breast cancer outcomes. Adv Exp Med Biol. 862:143–153. 2015. View Article : Google Scholar : PubMed/NCBI
29	Farooqi AA, Tang JY, Li RN, Ismail M, Chang YT, Shu CW, Yuan SS, Liu JR, Mansoor Q, Huang CJ and Chang HW: Epigenetic mechanisms in cancer: Push and pull between kneaded erasers and fate writers. Int J Nanomedicine. 10:3183–3191. 2015.PubMed/NCBI